I agree that this site is using cookies. You can find further informations here.
X
Advani, R.N.
703  results:
Search for persons X
?
1

Operation of a 3 MW, 140 GHz gyrotron with a coaxial cavity:

, In: 25th Anniversary, IEEE Conference Record - Abstracts. 1998 IEEE International Conference on Plasma Science (Cat. No.98CH36221),
Advani, R.N. ; Pedrozzi, M. ; Kreischer, K.E... - p. 235,236 , 1998
Link: https://doi.org/10.1109/..
 
?
2

Analysis or ferroelectric emission using initial energy eff..:

, In: IEEE Conference Record - Abstracts. 1996 IEEE International Conference on Plasma Science,
Advani, R.N. ; Kreischer, K.E. ; Temkin, R.J. - p. 136 , 1996
Link: https://doi.org/10.1109/..
 
?
3

Characterization of carbon fiber flocked cathode materials:

, In: IEEE Conference Record - Abstracts. 1996 IEEE International Conference on Plasma Science,
Visosky, M.M. ; Advani, R.N. ; Bekefi, G.... - p. 139 , 1996
Link: https://doi.org/10.1109/..
 
?
4

OUTCOMES OF AUTOLOGOUS TRANSPLANT, ALLOGENEIC TRANSPLANT, A..:

Messmer, M. ; Stack, A. ; Deng, M....
Hematological Oncology.  41 (2023)  S2 - p. 156-158 , 2023
Link: https://doi.org/10.1002/..
 
?
5

The ECHELON-2 Trial: 5-year results of a randomized, phase ..:

Horwitz, S. ; O'Connor, O.A. ; Pro, B....
Annals of Oncology.  33 (2022)  3 - p. 288-298 , 2022
Link: https://doi.org/10.1016/..
 
?
6

S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB..:

Hutchings, M. ; Ansell, S. M. ; Straus, D. J....
HemaSphere.  6 (2022)  - p. 101-102 , 2022
Link: https://doi.org/10.1097/..
 
?
7

S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN..:

Carlo-Stella, C. ; Ansell, S. ; Zinzani, P. L...
HemaSphere.  6 (2022)  - p. 102-103 , 2022
Link: https://doi.org/10.1097/..
 
?
8

THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 + RITUXIMAB ..:

Advani, R. ; Bartlett, N.L. ; Smith, S.M....
Hematological Oncology.  37 (2019)  S2 - p. 89-90 , 2019
Link: https://doi.org/10.1002/..
 
?
9

RESPONSE TO A+CHP BY CD30 EXPRESSION IN THE ECHELON‐2 TRIAL:

Illidge, T. ; Horwitz, S. ; Iyer, S....
Hematological Oncology.  37 (2019)  S2 - p. 281-283 , 2019
Link: https://doi.org/10.1002/..
 
?
10

BET INHIBITOR RG6146, VENETOCLAX, AND RITUXIMAB IS A HIGHLY..:

Dickinson, M. ; Briones Mejjide, J. ; Herrera, A.F....
Hematological Oncology.  37 (2019)  S2 - p. 174-175 , 2019
Link: https://doi.org/10.1002/..
 
?
11

CLINICAL ACTIVITY OF REGN1979, AN ANTI‐CD20 X ANTI‐CD3 BISP..:

Topp, M.S. ; Arnason, J. ; Advani, R....
Hematological Oncology.  37 (2019)  S2 - p. 90-92 , 2019
Link: https://doi.org/10.1002/..
 
?
12

EXTENDED FOLLOW‐UP OF A PHASE I TRIAL OF IPILIMUMAB, NIVOLU..:

Diefenbach, C.S. ; Hong, F. ; Ambinder, R....
Hematological Oncology.  37 (2019)  S2 - p. 123-124 , 2019
Link: https://doi.org/10.1002/..
 
?
13

RESPONSE TO BRENTUXIMAB VEDOTIN BY CD30 EXPRESSION: RESULTS..:

Jagadeesh, D. ; Horwitz, S. ; Bartlett, N.L....
Hematological Oncology.  37 (2019)  S2 - p. 470-471 , 2019
Link: https://doi.org/10.1002/..
 
?
14

PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THER..:

Lunning, M. ; Horwitz, S. ; Advani, R....
Hematological Oncology.  37 (2019)  S2 - p. 280-281 , 2019
Link: https://doi.org/10.1002/..
 
?
15

A PILOT STUDY OF BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY F..:

Kumar, A. ; Casulo, C. ; Advani, R....
Hematological Oncology.  35 (2017)  S2 - p. 171-172 , 2017
Link: https://doi.org/10.1002/..
 
1-15